Status:
COMPLETED
Irinotecan in Treating Asian Patients With Solid Tumors
Lead Sponsor:
National Cancer Centre, Singapore
Conditions:
Unspecified Adult Solid Tumor, Protocol Specific
Eligibility:
All Genders
21-120 years
Phase:
PHASE1
Brief Summary
RATIONALE: Drugs used in chemotherapy, such as irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase...
Detailed Description
OBJECTIVES: Primary * To determine the dose-limiting toxicity and maximum tolerated dose of irinotecan hydrochloride according to the genotype status of Asian patients with solid tumors. Secondary ...
Eligibility Criteria
Inclusion
- DISEASE CHARACTERISTICS:
- Histologically or cytologically confirmed solid tumors
- Failed at least one line of prior chemotherapy
- Must belong to either Chinese, Malay, or Indian ethnic groups
- Previously irradiated disease allowed provided marker lesions not within the irradiated field
- Presence of at least one bidimensionally measurable, non-CNS indicator lesion, defined by radiologic study (including CT or MRI scan, ultrasound, or chest X-ray) or physical exam, meeting 1 of the following criteria:
- Measurable disease on CT or MRI scan must have one diameter ≥ 1 cm and one diameter ≥ 2 cm
- Measurable disease on chest X-ray or ultrasound must have both diameters ≥ 2 cm
- Palpable tumor masses that cannot be evaluated radiologically must have two diameters ≥ 2 cm
- Measurable skin lesion must have at least one diameter ≥ 1 cm
- No unidimensionally measurable or evaluable only disease
- No known brain or leptomeningeal metastasis
- No uncontrolled large pleural effusions
- PATIENT CHARACTERISTICS:
- ECOG performance status 0-2
- Life expectancy ≥ 3 months
- Absolute granulocyte count ≥ 1,000/µL
- WBC ≥ 3,500/µL
- Hemoglobin ≥ 9 g/dL
- Platelet count ≥ 100,000/µL
- Serum total bilirubin ≤ 2.0 mg/dL
- ALT/AST \< 2.5 times normal (5 times normal in patients with known metastatic disease in the liver)
- Creatinine clearance ≥ 60 mL/min
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
- No medical problems severe enough to prevent compliance with the study requirements
- No prior malignancies, except for adequately treated basal cell or squamous cell carcinoma, carcinoma in situ of the cervix, or other cancer for which the patient has been disease-free for 5 years
- No active or uncontrolled infection
- No pre-existing cardiac disease, including congestive heart failure, arrhythmia requiring treatment, or myocardial infarction within the past 3 months
- No pneumonitis
- No uncontrolled diabetes mellitus (i.e., random blood glucose \> 200 mg/dL)
- No inflammatory bowel disease
- PRIOR CONCURRENT THERAPY:
- At least 1 week since prior and no concurrent ketoconazole
- More than 4 weeks since prior chemotherapy or radiotherapy
- At least 2 weeks since prior and no concurrent Hypericum perforatum (St. John wort)
- No prior irinotecan hydrochloride
- No concurrent investigational antineoplastic therapy or other investigational drugs
Exclusion
Key Trial Info
Start Date :
April 3 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2016
Estimated Enrollment :
18 Patients enrolled
Trial Details
Trial ID
NCT00731276
Start Date
April 3 2008
End Date
April 1 2016
Last Update
March 31 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Cancer Centre - Singapore
Singapore, Singapore, 169610